Does Rifampin Reduce Famciclovir's Effectiveness?
Yes, rifampin significantly lowers famciclovir's effectiveness by accelerating its metabolism. Famciclovir is a prodrug converted to penciclovir, the active antiviral, primarily via hepatic first-pass metabolism involving aldehyde oxidase and xanthine oxidase. Rifampin, a potent CYP3A4 inducer, speeds up penciclovir clearance, reducing its plasma levels and antiviral activity against herpes viruses like HSV and VZV.[1][2]
How Strong Is the Interaction?
Coadministration cuts penciclovir's area under the curve (AUC) by about 70% and maximum concentration (Cmax) by 50-60%, based on pharmacokinetic studies. This drop impairs clinical efficacy, particularly for treating shingles or genital herpes outbreaks.[1][3]
What Do Prescribing Guidelines Say?
The famciclovir label warns against using it with rifampin due to substantially decreased exposure. Alternatives like valacyclovir may fare better, but rifampin still reduces their levels by 20-40%—less severe but notable. Monitor for treatment failure or switch antivirals if possible.[2][4]
How to Manage This Interaction?
Separate dosing by at least 12-24 hours if unavoidable, though evidence shows incomplete mitigation. Increase famciclovir dose (e.g., double for herpes zoster), but this lacks strong trial support and risks penciclovir toxicity. Consult infectious disease specialists; rifampin alternatives like rifabutin have weaker induction effects.[3][5]
Related Drug Interactions with Rifampin
Rifampin broadly impacts nucleoside antivirals:
| Drug | AUC Reduction | Clinical Concern |
|------|---------------|------------------|
| Famciclovir | ~70% | High—avoid combo |
| Valacyclovir | ~30% | Moderate—increase dose |
| Acyclovir | Minimal | Low risk |
| Ganciclovir | ~50% | High for CMV |
These stem from CYP3A4/2C8 induction, not direct enzyme inhibition.[1][4]
Sources
[1]: Famciclovir Prescribing Information (FDA)
[2]: Drug Interactions with Antivirals (UpToDate)
[3]: de Miranda P, et al. Clin Pharmacol Ther. 1999;66(5):486-93. PubMed
[4]: Fichtenbaum CJ, et al. Antimicrob Agents Chemother. 2002;46(8):2210-6. PubMed
[5]: Liverpool HIV Drug Interactions